Lista de obras -

An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir

artículo científico publicado en 2005

Chronological and biological age in HIV infection

artículo científico publicado en 2010

Comparison of Monocyte Distribution Width (MDW) and Procalcitonin for early recognition of sepsis

artículo científico publicado en 2020

Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district

scientific article published on 14 September 2016

Decrease of renal function in HCV and HIV/HCV-infected patients with telaprevir-based therapy.

artículo científico publicado en 2015

Decreasing cardiovascular risk in HIV infection between 2005 and 2011.

artículo científico publicado en 2014

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project.

artículo científico publicado en 2018

Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?

artículo científico publicado en 2015

Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome

artículo científico publicado en 2014

Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study

artículo científico publicado en 2008

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

artículo científico publicado en 2017

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study

scientific article published on 09 July 2020

Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice

artículo científico publicado en 2014

Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia

artículo científico publicado en 2010

May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics

artículo científico publicado en 2015

Metabolic Syndrome: A Real Threat for HIV-Positive Patients?

article

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

artículo científico publicado en 2017

Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance

artículo científico publicado en 2014

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program

artículo científico publicado en 2016

Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study

artículo científico publicado en 2017

Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study

artículo científico publicado en 2011

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.

artículo científico publicado en 2018

Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study

artículo científico publicado en 2012

Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin

artículo científico publicado en 2010

Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere et al' by Buckley

artículo científico publicado en 2020

Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma

artículo científico publicado en 2020

Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment

artículo científico publicado en 2013

Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project).

artículo científico publicado en 2012

Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study

artículo científico publicado en 2016

The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients

artículo científico publicado en 2013

Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension Study

artículo científico publicado en 2017

Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients

artículo científico publicado en 2018

Lista de obras de

An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir

Chronological and biological age in HIV infection

Comparison of Monocyte Distribution Width (MDW) and Procalcitonin for early recognition of sepsis

Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district

Decrease of renal function in HCV and HIV/HCV-infected patients with telaprevir-based therapy.

Decreasing cardiovascular risk in HIV infection between 2005 and 2011.

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project.

Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?

Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome

Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study

Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice

Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia

May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics

Metabolic Syndrome: A Real Threat for HIV-Positive Patients?

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program

Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study

Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.

Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study

Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin

Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere et al' by Buckley

Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma

Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment

Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project).

Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study

The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients

Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension Study

Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients